Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement by Petrou, S et al.
COMMENTARY Open Access
Preferred reporting items for studies
mapping onto preference-based outcome
measures: The MAPS statement
Stavros Petrou1*, Oliver Rivero-Arias2, Helen Dakin3, Louise Longworth4, Mark Oppe5, Robert Froud1,6
and Alastair Gray3
Abstract
‘Mapping’ onto generic preference-based outcome measures is increasingly being used as a means of generating
health utilities for use within health economic evaluations. Despite publication of technical guides for the conduct
of mapping research, guidance for the reporting of mapping studies is currently lacking. The MAPS (MApping onto
Preference-based measures reporting Standards) statement is a new checklist, which aims to promote complete
and transparent reporting of mapping studies. The primary audiences for the MAPS statement are researchers
reporting mapping studies, the funders of the research, and peer reviewers and editors involved in assessing
mapping studies for publication.
A de novo list of 29 candidate reporting items and accompanying explanations was created by a working group
comprised of six health economists and one Delphi methodologist. Following a two-round, modified Delphi survey
with representatives from academia, consultancy, health technology assessment agencies and the biomedical
journal editorial community, a final set of 23 items deemed essential for transparent reporting, and accompanying
explanations, was developed. The items are contained in a user friendly 23 item checklist. They are presented
numerically and categorised within six sections, namely: (i) title and abstract; (ii) introduction; (iii) methods; (iv)
results; (v) discussion; and (vi) other. The MAPS statement is best applied in conjunction with the accompanying
MAPS explanation and elaboration document.
It is anticipated that the MAPS statement will improve the clarity, transparency and completeness of reporting of
mapping studies. To facilitate dissemination and uptake, the MAPS statement is being co-published by eight health
economics and quality of life journals, and broader endorsement is encouraged. The MAPS working group plans to
assess the need for an update of the reporting checklist in five years’ time.
This statement was published jointly in Applied Health Economics and Health Policy, Health and Quality of Life
Outcomes, International Journal of Technology Assessment in Health Care, Journal of Medical Economics, Medical
Decision Making, PharmacoEconomics, and Quality of Life Research.
Introduction
The process of ‘mapping’ onto generic preference-based
outcome measures is increasingly being used as a means
of generating health utilities for application within health
economic evaluations [1]. Mapping involves the develop-
ment and use of an algorithm (or algorithms) to predict
the primary outputs of generic preference-based outcome
measures, i.e. health utility values, using data on other in-
dicators or measures of health. The source predictive
measure may be a non-preference based indicator or
measure of health outcome or, more exceptionally, a
preference-based outcome measure that is not preferred
by the local health technology assessment agency. The al-
gorithm(s) can subsequently be applied to data from clin-
ical trials, observational studies or economic models
containing the source predictive measure(s) to predict
health utility values in contexts where the target generic
preference-based measure is absent. The predicted health
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utility values can then be analysed using standard methods
for individual-level data (e.g. within a trial-based economic
evaluation), or summarised for each health state within a
decision-analytic model.
Over recent years there has been a rapid increase in
the publication of studies that use mapping techniques
to predict health utility values, and databases of pub-
lished studies in this field are beginning to emerge [2].
Some authors [3] and agencies [4] concerned with tech-
nology appraisals have issued technical guides for the
conduct of mapping research. However, guidance for the
reporting of mapping studies is currently lacking. In
keeping with health-related research more broadly [5],
mapping studies should be reported fully and transpar-
ently to allow readers to assess the relative merits of the
investigation [6]. Moreover, there may be significant op-
portunity costs associated with regulatory and reim-
bursement decisions for new technologies informed by
misleading findings from mapping studies. This has led
to the development of the MAPS (MApping onto
Preference-based measures reporting Standards) report-
ing statement, which we summarise in this paper.
The aim of the MAPS reporting statement is to pro-
vide recommendations, in the form of a checklist of es-
sential items, which authors should consider when
reporting a mapping study. It is anticipated that the
checklist will promote complete and transparent report-
ing by researchers. The focus, therefore, is on promoting
the quality of reporting of mapping studies, rather than
the quality of their conduct, although it is possible that
the reporting statement will also indirectly enhance the
methodological rigour of the research [7]. The MAPS
reporting statement is primarily targeted at researchers
developing mapping algorithms, the funders of the re-
search, and peer reviewers and editors involved in the
manuscript review process for mapping studies [5, 6]. In
developing the reporting statement, the term ‘mapping’
is used to cover all approaches that predict the outputs
of generic preference-based outcome measures using
data on other indicators or measures of health, and en-
compasses related forms of nomenclature used by some
researchers, such as ‘cross-walking’ or ‘transfer to utility’
[1, 8]. Similarly, the term ‘algorithm’ is used in its broad-
est sense to encompass statistical associations and more
complex series of operations.
The development of the MAPS statement
The development of the MAPS reporting statement was
informed by recently published guidance for health re-
search reporting guidelines [5] and broadly modelled
other recent reporting guideline developments [9–14]. A
working group comprised of six health economists (SP,
ORA, HD, LL, MO, AG) and one Delphi methodologist
(RF) was formed following a request from an academic
journal to develop a reporting statement for mapping
studies. One of the working group members (HD) had
previously conducted a systematic review of studies map-
ping from clinical or health-related quality of life measures
onto the EQ-5D [2]. Using the search terms from this sys-
tematic review, as well as other relevant articles and re-
ports already in our possession, a broad search for
reporting guidelines for mapping studies was conducted.
This confirmed that no previous reporting guidance had
been published. The working group members therefore
developed a preliminary de novo list of 29 reporting items
and accompanying explanations. Following further review
by the working group members, this was subsequently dis-
tilled into a list of 25 reporting items and accompanying
explanations.
Members of the working group identified 62 possible
candidates for a Delphi panel from a pool of active re-
searchers and stakeholders in this field. The candidates
included individuals from academic and consultancy set-
tings with considerable experience in mapping research,
representatives from health technology assessment agen-
cies that routinely appraise evidence informed by map-
ping studies, and biomedical journal editors. Health
economists from the MAPS working group were in-
cluded in the Delphi panel. A total of 48 of the 62
(77.4 %) individuals agreed to participate in a Delphi sur-
vey aimed at developing a minimum set of standard
reporting requirements for mapping studies with an ac-
companying reporting checklist.
The Delphi panellists were sent a personalised link to
a Web-based survey, which had been piloted by mem-
bers of the working group. Non-responders were sent up
to two reminders after 14 and 21 days. The panellists
were anonymous to each other throughout the study
and their identities were known only to one member of
the working group. The panellists were invited to rate
the importance of each of the 25 candidate reporting
items identified by the working group on a 9-point rat-
ing scale (1, “not important”, to 9, “extremely import-
ant”); describe their confidence in their ratings (“not
confident”, “somewhat confident” or “very confident”);
comment on the candidate items and their explanations;
suggest additional items for consideration by the panel-
lists in subsequent rounds; and to provide any other
general comments. The candidate reporting items were
ordered within six sections: (i) title and abstract; (ii)
introduction; (iii) methods; (iv) results; (v) discussion;
and (vi) other. The panellists also provided information
about their geographical area of work, gender, and pri-
mary and additional work environments. The data were
imported into Stata (version 13; Stata-Corp, College
Station, TX) for analysis.
A modified version of the Research ANd Development
(RAND)/ University of California Los Angeles (UCLA)
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appropriateness method was used to analyse the round
one responses [15]. This involved calculating the median
score, the inter-percentile range (IPR) (30th and 70th),
and the inter-percentile range adjusted for symmetry
(IPRAS), for each item (i) being rated. The IPRAS in-
cludes a correction factor for asymmetric ratings, and
panel disagreement was judged to be present in cases if
IPRi > IPRASi [15]. We modified the RAND/UCLA ap-
proach by asking panellists about ‘importance’ rather
than ‘appropriateness’ per se. Assessment of importance
followed the classic RAND/UCLA definitions, cate-
gorised simply as whether the median rating fell between
1 and 3 (unimportant), 4 and 6 (neither unimportant
nor important), or 7 and 9 (important) [15].
The results of round one of the Delphi survey were
reviewed at a face-to-face meeting of the working group.
A total of 46 of the 48 (95.8 %) individuals who agreed
to participate completed round one of the survey. Of the
25 items, 24 were rated as important, with one item
(“Source of Funding”) rated as neither unimportant nor
important. There was no evidence of disagreement on
ratings of any items according to the RAND/UCLA
method. These findings did not change when the responses
of the MAPS working group were excluded. Based on the
qualitative feedback received in round one, items describing
“Modelling Approaches” and “Repeated Measurements”
were merged, as were items describing “Model Diagnostics”
and “Model Plausibility”. In addition, amendments to the
wording of several recommendations and their explanations
were made in the light of qualitative feedback from the
panellists.
Panellists participating in round one were invited to
participate in a second round of the Delphi survey. A
summary of revisions made following round one was
provided. This included a document in which revisions
to each of the recommendations and explanations were
displayed in the form of track changes. Panellists partici-
pating in round two were provided with group outputs
(mean scores and their standard deviations, median
scores and their IPRs, histograms and RAND/UCLA la-
bels of importance and agreement level) summarising
the round one results (and disaggregated outputs for the
merged items). They were also able to view their own
round one scores for each item (and disaggregated
scores for the merged items). Panellists participating in
round two were offered the opportunity to revise their
rating of the importance of each of the items and in-
formed that their rating from round one would other-
wise hold. For the merged items, new ratings were
solicited. Panellists participating in round two were also
offered the opportunity to provide any further com-
ments on each item or any further information that
might be helpful to the group. Non-responders to the
second round of the Delphi survey were sent up to two
reminders after 14 and 21 days. The analytical methods
for the round two data mirrored those for the first
round.
The results of the second round of the Delphi survey
were reviewed at a face-to-face meeting of the working
group. A total of 39 of the 46 (84.8 %) panellists partici-
pating in round one completed round two of the survey.
All 23 items included in the second round were rated as
important with no evidence of disagreement on ratings
of any items according to the RAND/UCLA method.
Qualitative feedback from the panellists participating in
round two led to minor modifications to wording of a
small number of recommendations and their explana-
tions. This was fed back to the round two respondents
who were given a final opportunity to comment on the
readability of the final set of recommendations and ex-
planations. Based on these methods, a final consensus
list of 23 reporting items was developed.
The MAPS statement
The MAPS statement is a 23-item checklist of recom-
mendations (Table 1) that we consider essential for
complete and transparent reporting of studies that map
onto generic preference-based outcome measures. The
23 reporting items are presented numerically and cate-
gorised within six sections, namely: (i) title and abstract
(2 items); (ii) introduction (2 items); (iii) methods (9
items); (iv) results (6 items); (v) discussion (3 items); and
(vi) other (1 item). The reporting of each item does not
necessarily have to follow the order within the MAPS
statement. Rather, what is important is that each recom-
mendation is addressed either in the main body of the re-
port or its appendices. Several biomedical journals have
endorsed the MAPS statement. These include Applied
Health Economics and Health Policy, Health and Quality
of Life Outcomes, International Journal of Technology As-
sessment in Health Care, Journal of Medical Economics,
Medical Decision Making, PharmacoEconomics and Qual-
ity of Life Research. We encourage other journals and re-
search interest groups to endorse the MAPS statement
and authors to adhere to its principles.
The MAPS explanation and elaboration paper
In addition to the MAPS reporting statement, we have
produced a supporting Explanation and Elaboration paper
[16] modelled on those developed for other reporting
guidelines [9–14]. The reporting items contained within
the MAPS statement are best understood by referring to
the information contained within this accompanying
document. The Explanation and Elaboration paper pro-
vides exemplars of good reporting practice identified from
the published literature for each reporting item. In
addition, it provides a detailed explanation to accompany
each recommendation, supported by a rationale and
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Table 1 Checklist of items to include when reporting a mapping study
Section/topic Item
number
Recommendation Reported on page
number/line
number
Title and abstract
Title 1 Identify the report as a study mapping between outcome measures.
State the source measure(s) and generic, preference-based target
measure(s) used in the study.
_____________
Abstract 2 Provide a structured abstract including, as applicable: objectives; methods,
including data sources and their key characteristics, outcome measures
used and estimation and validation strategies; results, including indicators
of model performance; conclusions; and implications of key findings.
_____________
Introduction
Study rationale 3 Describe the rationale for the mapping study in the context of the
broader evidence base.
_____________
Study objective 4 Specify the research question with reference to the source and target
measures used and the disease or population context of the study.
_____________
Methods
Estimation sample 5 Describe how the estimation sample was identified, why it was selected,
the methods of recruitment and data collection, and its location(s) or
setting(s).
_____________
External validation
sample
6 If an external validation sample was used, the rationale for selection,
the methods of recruitment and data collection, and its location(s) or
setting(s) should be described.
____________
Source and target
measures
7 Describe the source and target measures and the methods by which
they were applied in the mapping study.
_____________
Exploratory data
analysis
8 Describe the methods used to assess the degree of conceptual overlap
between the source and target measures.
_____________
Missing data 9 State how much data were missing and how missing data were handled
in the sample(s) used for the analyses.
_____________
Modelling approaches 10 Describe and justify the statistical model(s) used to develop the
mapping algorithm.
_____________
Estimation of
predicted scores
or utilities
11 Describe how predicted scores or utilities are estimated for each
model specification.
_____________
Validation methods 12 Describe and justify the methods used to validate the mapping algorithm. _____________
Measures of model
performance
13 State and justify the measure(s) of model performance that determine
the choice of the preferred model(s) and describe how these measures
were estimated and applied.
_____________
Results
Final sample size(s) 14 State the size of the estimation sample and any validation sample(s)
used in the analyses (including both number of individuals and number
of observations).
_____________
Descriptive information 15 Describe the characteristics of individuals in the sample(s) (or refer
back to previous publications giving such information). Provide summary
scores for source and target measures, and summarise results of analyses
used to assess overlap between the source and target measures.
_____________
Model selection 16 State which model(s) is(are) preferred and justify why this(these) model(s)
was(were) chosen.
_____________
Model coefficients 17 Provide all model coefficients and standard errors for the selected model(s).
Provide clear guidance on how a user can calculate utility scores based
on the outputs of the selected model(s).
_____________
Uncertainty 18 Report information that enables users to estimate standard errors
around mean utility predictions and individual-level variability.
_____________
Model performance
and face validity
19 Present results of model performance, such as measures of prediction
accuracy and fit statistics for the selected model(s) in a table or in the
text. Provide an assessment of face validity of the selected model(s).
_____________
Petrou et al. Health and Quality of Life Outcomes  (2015) 13:106 Page 4 of 7
relevant evidence where available. The development of the
Explanation and Elaboration paper was completed follow-
ing several iterations produced by members of the work-
ing group, after which the examples and explanations
were shared with the Delphi panellists for final revisions
to improve readability and their approval. The Explanation
and Elaboration paper also summarises the characteristics
of the Delphi panellists and provides detailed statistics for
item ratings at each Delphi round.
Discussion
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to
predict health utility values. One recent review article
identified ninety studies published up to the year 2013
reporting 121 mapping algorithms between clinical or
health-related quality of life measures and the EQ-5D
[2]. That review article excluded mapping algorithms
targeted at other generic preference-based outcome
measures that can generate health utilities, such as the
SF-6D [17] and the Health Utilities Index (HUI) [18],
which have been the target of numerous other mapping
algorithms (e.g. [19–24, 1]). Moreover, the popularity of
the mapping approach for estimating health utilities is
unlikely to wane given the numerous contexts within
health economic evaluation where primary data collec-
tion is challenging. However, mapping introduces add-
itional uncertainty and collection of primary data with
the preferred utility instrument is preferable.
The MAPS reporting statement was developed to pro-
vide recommendations, in the form of a checklist of es-
sential items, which authors should consider when
reporting mapping studies. Guidance for the reporting
of mapping studies was not previously available in the
literature. The overall aim of MAPS is to promote clarity,
transparency and completeness of reporting of mapping
studies. It is not intended to act as a methodological guide,
nor as a tool for assessing the quality of study method-
ology. Rather, it aims to avoid misleading conclusions
being drawn by readers, and ultimately policy makers, as a
result of sub-optimal reporting. In keeping with other re-
cent health research reporting guidelines, we have also
produced an accompanying Explanation and Elaboration
paper [16] to facilitate a deeper understanding of the 23
items contained within the MAPS reporting statement.
That paper should hopefully act as a pedagogical frame-
work for researchers reporting mapping studies.
The development of the MAPS reporting statement,
and its Explanation and Elaboration document, was
framed by recently published guidance for health re-
search reporting guidelines [5]. The Delphi panel was
composed of a multi-disciplinary, multi-national team of
content experts and journal editors. The panel members
included people experienced in conducting mapping
studies; of the 84 researchers who were first authors on
papers included in a recent review of EQ-5D mapping
studies [2], 31 (36.9 %) were included as panellists. We
have no evidence to believe that a larger panel would
have altered the final set of recommendations. The Del-
phi methodologies that we applied included analytical
approaches only recently adopted by developers of
health reporting guidelines [15]. We are unable to assess
whether a strict adherence to the MAPS checklist will
increase the word counts of mapping reports. It is our
view that the increasing use of online appendices by jour-
nals should permit comprehensive reporting even in the
context of strict word limits for the main body of reports.
Evidence for other health research reporting guidelines
suggests that reporting quality improved after the intro-
duction of reporting checklists [25–27], although there
is currently no empirical evidence that adoption of
MAPS will improve the quality of reporting of mapping
research. Future research planned by the MAPS working
group will include a before and after evaluation of the ben-
efits (and indeed possible adverse effects) of the introduc-
tion of the MAPS reporting statement. It will also be
necessary to update the MAPS reporting statement in the
future to address conceptual, methodological and practical
Table 1 Checklist of items to include when reporting a mapping study (Continued)
Discussion
Comparisons with
previous studies
20 Report details of previously published studies developing mapping
algorithms
between the same source and target measures and describe differences
between the algorithms, in terms of model performance, predictions
and coefficients, if applicable.
_____________
Study limitations 21 Outline the potential limitations of the mapping algorithm. _____________
Scope of
applications
22 Outline the clinical and research settings in which the mapping algorithm
could be used.
_____________
Other
Additional
information
23 Describe the source(s) of funding and non-monetary support for the study,
and the role of the funder(s) in its design, conduct and report. Report
any conflicts of interest surrounding the roles of authors and funders.
_____________
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advances in the field. Potential methodological advances
that might be reflected in an update might include shifts
towards more complex model specifications, better
methods for dealing with uncertainty, and guidance on ap-
propriate use of measures of prediction accuracy, such as
mean absolute error (MAE) and mean square error
(MSE). The MAPS working group plans to assess the need
for an update of the reporting checklist in five years’ time.
In conclusion, this paper summarises a new reporting
statement developed for studies that map onto generic
preference-based outcome measures. We encourage
health economic and quality of life journals to endorse
MAPS, promote its use in peer review and update their
editorial requirements and ‘Instructions to Authors’
accordingly.
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